financetom
Business
financetom
/
Business
/
Lululemon Athletica Takes 'Thoughtful' Approach in China, Growth Expectations May Be Overly Optimistic, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lululemon Athletica Takes 'Thoughtful' Approach in China, Growth Expectations May Be Overly Optimistic, Morgan Stanley Says
Oct 2, 2024 10:26 PM

01:01 PM EDT, 10/01/2024 (MT Newswires) -- Lululemon Athletica ( LULU ) has adopted a "thoughtful" approach in China but the company's international growth objectives for the next quarter need to be reassessed as it might not achieve as much as anticipated, Morgan Stanley said in a note Tuesday.

The brokerage's analysis of China highlights Lululemon's success in the region, which it attributes to its strategic entry and relevant brand positioning. "While that's impressive, our work shows forward expectations may be too high for China/int'l, leading us to trim our [medium-term] estimates," Morgan Stanley said.

"[Lululemon] is one of few Western specialty retailers to successfully enter China, & already represents the 3rd largest non domestic sports apparel player in the region," Morgan Stanley said, adding that the company may need to reassess its medium-term international growth targets.

Morgan Stanley's analysis indicates that Lululemon's market share in the Chinese sports apparel industry will grow at a rate similar to the last five years, adding that the revenue in China could surpass $2.7 billion by 2028, representing 7.5% of the market.

The brokerage expects a low 20% compound annual growth rate over the next 3-5 years considering Lululemon's market share in China increases at the same rate as it did in North America when it achieved a similar market position.

Morgan Stanley maintained an overweight rating on Lululemon's stock and trimmed its price target to $314 from $326.

Price: 263.99, Change: -7.36, Percent Change: -2.71

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved